| | Variables | Total (n = 155) | AKI group (n = 27) | Non-AKI group (n = 128) | value |
| | Demography | | Age (years) | 61 ± 12 | 65 ± 14 | 61 ± 12 | 0.457 | | Female (%) | 20(12.9) | 9 (33.3) | 11 (8.6) | 0.002 | | Hypertension (%) | 83 (53.5) | 15 (55.6) | 68 (53.1) | 0.818 | | DM (%) | 84 (29.5) | 7 (25.9) | 37 (28.9) | 0.755 | | Prior MI (%) | 22 (14.2) | 4 (14.8) | 18 (14.1) | 0.561 | | CHF (%) | 3 (1.9) | 1 (3.7) | 2 (1.6) | 0.439 | | CKD (%) | 8 (5.2) | 7 (25.9) | 1 (0.8) | <0.001 | | Cerebral infarction (%) | 22 (14.2) | 7 (25.9) | 15 (11.7) | 0.069 | | Previous PCI (%) | 19 (12.3) | 3 (11.1) | 16 (12.5) | 0.570 | | Previous CABG (%) | 1 (0.1) | 0 (0.0) | 1 (0.8) | 0.826 | | Chronic lung disease (%) | 4 (2.6) | 2 (7.4) | 2 (1.6) | 0.140 | | Dislipidemia (%) | 26 (16.8) | 7 (25.9) | 19 (14.8) | 0.166 | | Smoking history (%) | 108 (69.7) | 16 (59.3) | 92 (71.9) | 0.195 |
| | Clinical presentation | | Systolic pressure (mmHg) | 121 ± 25 | 104 ± 31 | 124 ± 22 | 0.014 | | Diastolic pressure (mmHg) | 72 ± 16 | 62 ± 16 | 74 ± 15 | 0.079 | | Heart rate (bpm) | 76 (68, 90) | 96(83, 120) | 72(66, 84) | <0.001 | | STEMI (%) | 100 (64.5) | 23 (85.2) | 77 (60.2) | 0.014 | | Extensive anterior myocardial infarction (%) | 29 (18.7) | 15 (55.6) | 14 (10.9) | <0.001 | | Killip grade ≥III stage (%) | 15 (9.7) | 12 (52.2) | 3 (3.6) | <0.001 | | Cardiogenic shock (%) | 10 (6.5) | 9 (33.3) | 1 (0.8) | <0.001 | | Ventricular tachycardia or fibrillation (%) | 9 (5.8) | 7 (25.9) | 2 (1.6) | <0.001 | | Atrial fibrillation (%) | 11 (7.1) | 7 (25.9) | 4 (3.2) | <0.001 | | Atrioventricular block (%) | 1 (0.6) | 0 (0.0) | 1 (0.8) | 0.826 | | Acute heart failure (%) | 13 (8.4) | 11 (40.7) | 2 (1.6) | <0.001 |
| | Laboratory tests | | Hemoglobin (g/L) | 137 ± 20 | 126 ± 21 | 137 ± 19 | 0.007 | | WBC (×109/L) | 8.8 (6.9, 11.3) | 11.4 (8.8, 15.0) | 8.6 (6.8, 10.5) | 0.002 | | PLT (×109/L) | 196 ± 66 | 202 ± 77 | 208 ± 63 | 0.677 | | SCr at admission (μmol/L) | 73.0 ± 15.8 | 78.2 ± 20.4 | 73.3 ± 14.6 | 0.140 | | SCr Max (μmol/L) | 79.0 (67.0, 91.0) | 116.0 (103.0, 155.0) | 73.5 (64.3, 85.0) | <0.001 | | eGFR at admission (ml/min1.73 m2) | 92.77 (83.36, 100.46) | 84.70 (64.20, 95.49) | 93.99 (85.05, 101.22) | 0.001 | | The valley eGFR (ml/min1.73 m2) | 90.06(72.16, 99.35) | 48.21 (40.68, 67.38) | 93.80 (84.93, 101.22) | <0.001 | | BUN (mmol/l) | 5.55 (4.25, 7.06) | 7.69 (6.61, 10.20) | 5.11 (4.11, 6.50) | <0.001 | | TNI Max (ng/ml) | 10.5 (2.7, 55.0) | 78.0 (15.2, 81.0) | 7.8 (1.8, 30.9) | <0.001 | | CK-MB (U/L) | 39.9 (10.2, 190.0) | 228.3 (32.7, 300.0) | 33.9(7.9, 123.0) | <0.001 | | BNP at admission (ng/ml) | 148.5 (75.4, 288.8) | 300.0 (132.0, 977.0) | 124.5 (63.0, 250.5) | 0.001 | | BNP Max (ng/ml) | 167.0(79.7, 466.3) | 783.8 (300.0, 1599.0) | 131 (63.0, 270.0) | <0.001 | | FBG (mmol/L) | 6.35 (5.19, 8.40) | 7.55 (5.99, 10.68) | 6.20 (5.09, 8.11) | 0.010 | | Albumin (g/L) | 38.4 ± 3.8 | 36.5 ± 4.0 | 38.8 ± 3.7 | 0.005 | | CHO (mmol/L) | 4.37 ± 1.08 | 4.44 ± 0.88 | 4.36 ± 0.11 | 0.713 | | TG (mmol/L) | 1.51 (1.06, 2.07) | 1.27 (0.99, 2.13) | 1.55 (1.08, 2.07) | 0.295 | | LDL (mmol/L) | 2.74 ± 0.87 | 2.63 ± 0.79 | 2.76 ± 0.88 | 0.507 | | HDL (mmol/L) | 0.95 (0.83, 1.09) | 1.03 (0.86, 1.26) | 0.94 (0.82, 1.06) | 0.066 | | LVEF (%) | 60 ± 11 | 52 (38, 63) | 64 (58, 68) | <0.001 |
| | Therapies | | Use of furosemide (mg/d) | 0 (0, 20) | 40 (40, 80) | 0 (0, 10) | <0.001 | | Intravenous isosorbide dinitrate (%) | 104 (67.1) | 19 (70.4) | 85 (66.4) | 0.823 | | Nonuse of ACEI/ARB (%) | 54 (34.8) | 18 (66.7) | 36 (28.1) | <0.001 | | Use of β-blockers (%) | 130 (83.9) | 22 (82.5) | 108 (84.4) | 0.710 | | Use of statins (%) | 154 (99.4) | 26 (96.3) | 128 (100.0) | 0.221 | | Vasoactive medication (%) | 29 (18.7) | 17 (63.0) | 12 (9.4) | <0.001 | | IABP (%) | 12 (7.7) | 7 (25.9) | 5 (3.9) | 0.037 | | In-hospital PCI (%) | 111 (71.6) | 18 (66.7) | 93 (72.7) | 0.530 | | In-hospital CABG (%) | 10 (6.5) | 2 (7.4) | 8 (6.3) | 0.686 | | In-hospital mechanical ventilation (%) | 10 (6.5) | 5 (18.5) | 5 (3.9) | 0.005 | | Contrast volume (ml) | 200 (100, 228) | 200 (100, 300) | 200 (100, 225) | 0.480 | | Thrombolysis therapy (%) | 4 (2.6) | 1 (3.7) | 3 (3.6) | 0.685 |
|
|
Data expressed as mean ± standard deviation, n (%), or median (interquartile range). DM, diabetes mellitus; MI, myocardial infarction; CHF, congestive heart failure; CKD, chronic kidney disease; PCI, percutaneous coronary intervention. CABG, coronary artery bypass grafting; STEMI, ST-segment elevation myocardial infarction; SCr, serum creatine; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; LVEF, left ventricular ejection fraction; Vasoactive medication included dopamine, dobutamine, and norepinephrine. Compared with non-AKI group, was considered significantly. |
